Takeda Pharmaceuticals

Dublin, Ireland Founded: 1986 • Age: 40 yrs Acquired By Takeda
Rare disease treatments are developed by a specialty biopharmaceutical firm.
Request Access

About Takeda Pharmaceuticals

Takeda Pharmaceuticals is a company based in Dublin (Ireland) founded in 1986 was acquired by Takeda in May 2018. It operates as a Direct-to-Consumer (D2C), and Professional Services. Takeda Pharmaceuticals has raised $17 million across 2 funding rounds from investors including Takeda Pharmaceuticals. Takeda Pharmaceuticals has completed 16 acquisitions, including Advanced BioHealing, Baxalta and Bikam Pharmaceuticals. Takeda Pharmaceuticals offers products and services including Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines. Takeda Pharmaceuticals operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.

  • Headquarter Dublin, Ireland
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Takeda Pharmaceutical Company Limited
  • Date of Incorporation 22 Sep, 2017
  • Jurisdiction Gurgaon, Haryana, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $1.68 M (USD)
    24.41
    as on Mar 31, 2022
  • Net Profit
    $5.02 K (USD)
    4.94
    as on Mar 31, 2022
  • EBITDA
    $-375.83 K (USD)
    -158.6
    as on Mar 31, 2022
  • Total Equity Funding
    $17 M (USD)

    in 2 rounds

  • Latest Funding Round
    $15 M (USD), Series B

    Oct 30, 2013

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    Takeda

    (May 12, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Takeda Pharmaceuticals

Takeda Pharmaceuticals offers a comprehensive portfolio of products and services, including Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Developed for treating Narcolepsy Type 1 patients.

Innovated for rare and complex chronic diseases.

Created to address global infectious disease needs.

People of Takeda Pharmaceuticals
Headcount 10000+
Employee Profiles 1042
Board Members and Advisors 11
Employee Profiles
People
Faith Finley
Senior Research Associate
People
Rodello Palomares
Quality Control Supervisor-lab Operational Support & Compliance
People
Petr Galík
TBS Global Head Of Innovation, Analytics And Automation
People
Andrew S. Plump
Director, President of Research & Development

Unlock access to complete

Board Members and Advisors
people
Steven Gillis
External Director
people
Olivier Bohuon
External Director
people
Michel Orsinger
External Director
people
Jean-Luc Butel
External Director

Unlock access to complete

Funding Insights of Takeda Pharmaceuticals

Takeda Pharmaceuticals has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $15.0M
  • First Round

    (18 Jul 2011)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2013 Amount Series B - Takeda Pharmaceuticals Valuation

investors

Jul, 2011 Amount Series A - Takeda Pharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Takeda Pharmaceuticals

Takeda Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Takeda Pharmaceuticals

Takeda Pharmaceuticals has strategically engaged in corporate development activities, having acquired 16 companies. Notable acquisitions include Advanced BioHealing, Baxalta and Bikam Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Developer of therapies for orphan diseases and other disease conditions
2015
Passionately pursuing better treatments for adults and children with rare liver diseases.
2011
Recombinant collagen technology is developed for chronic wound healing treatments.
2010
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Takeda Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Takeda Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Takeda Pharmaceuticals

Takeda Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Vaccines for infectious diseases are developed using cell-free protein synthesis.
domain founded_year HQ Location
Novel anti-infectives for bacterial and fungal infections are developed.
domain founded_year HQ Location
Gene therapy platform is developed for chronic disease treatments.
domain founded_year HQ Location
Prophylactic vaccines for infectious diseases are developed and advanced.
domain founded_year HQ Location
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Takeda Pharmaceuticals

Frequently Asked Questions about Takeda Pharmaceuticals

When was Takeda Pharmaceuticals founded?

Takeda Pharmaceuticals was founded in 1986 and raised its 1st funding round 25 years after it was founded.

Where is Takeda Pharmaceuticals located?

Takeda Pharmaceuticals is headquartered in Dublin, Ireland.

Is Takeda Pharmaceuticals a funded company?

Takeda Pharmaceuticals is a funded company, having raised a total of $17M across 2 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Jul 18, 2011.

What is the annual revenue of Takeda Pharmaceuticals?

Annual revenue of Takeda Pharmaceuticals is $1.68M as on Mar 31, 2022.

What does Takeda Pharmaceuticals do?

Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. The company focuses on areas such as gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs across various sectors, aiming to improve health outcomes and transform lives worldwide. Operations span multiple countries, ensuring a broad impact on global health systems.

Who are the top competitors of Takeda Pharmaceuticals?

Takeda Pharmaceuticals's top competitors include Vaxcyte, Serum Institute of India and Biological E.

What products or services does Takeda Pharmaceuticals offer?

Takeda Pharmaceuticals offers Oveporexton (TAK-861), Plasma-Derived Therapies, and Vaccines.

How many acquisitions has Takeda Pharmaceuticals made?

Takeda Pharmaceuticals has made 16 acquisitions, including Advanced BioHealing, Baxalta, and Bikam Pharmaceuticals.

Who are Takeda Pharmaceuticals's investors?

Takeda Pharmaceuticals has 1 investor. Key investors include Takeda Pharmaceuticals.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available